



HEMATOLOGY, TRANSFUSION AND CELL THERAPY

www.htct.com.br



Letter to the Editor

Comment on “Risk factors associated with the use of red blood cells in elective cardiac surgeries”

1 Dear Editor,

2 We herein discuss the publication on “Risk factors associated
3 with the use of red blood cells in elective cardiac surgeries: A
4 patient blood management (PBM) view”. [1] This article inves-
5 tigates the risk variables linked with the use of packed red
6 blood cells (PRBC) in patients undergoing elective heart sur-
7 gery in Brazil.

8 While stepwise logistic regression results show that female
9 gender, poor hematocrit level, diabetes, and extracorporeal cir-
10 culation duration of more than 90 min are significant risk variables,
11 this analysis is statistically limited. As this is a retrospective
12 study, it is susceptible to bias from data collection or sample
13 selection. Furthermore, stepwise logistic regression may result in
14 overfitting and variable selection based on the specific data set,
15 restricting its applicability to other hospitals or populations.

16 Furthermore, underlying heart disease severity, changes in
17 surgeon treatment, surgical technique, or anticoagulant use can
18 all have an impact on the accuracy of the outcomes as these
19 variables may not be recorded or controlled in the analysis. Fur-
20 thermore, the identification of female gender as a high-risk fac-
21 tor could be explained by variations in body weight or total
22 blood volume, however the paper did not account for these var-
23 iables in its analysis. This may confound the relationship.

24 New interpretations may concentrate on synthesizing
25 findings for PBM guidelines. Preoperative hematocrit assess-
26 ment and improvement of anemia, diabetes management,
27 and surgical planning to limit cardiopulmonary bypass time
28 can all help to lessen the requirement for PRBC. Furthermore,
29 including risk prediction models that take into account char-
30 acteristics such as gender, body weight, disease severity, and
31 laboratory results might improve accuracy and simplify effec-
32 tive blood use planning.

33 To broaden the topic, consider the following research
34 questions:

- 2) How much can enhancing PBM with preoperative optimi- 38
zation techniques reduce PRBC use and clinical outcomes? 39
- 3) How do individual characteristics, such as body mass 40
index and female gender, affect overall blood volume? 41
- 4) Can multivariate machine learning algorithms accurately 42
predict the requirement for PRBC in cardiac surgery 43
patients? 44

These questions may lead to applicable research as well as 45
safe, resource-saving strategies in Brazil’s health-care sys- 46
tem. 47

Data availability statement

there Is no new data generated

Funding statement

there is no funding

Ethics of approval statement

not applicable

Patient consent statement

not applicable

Permission to reproduce material from other sources

not applicable

Clinical trial registration

not applicable

Author contributions

HP 50 % ideas, writing, analyzing, approval
VW 50 % ideas, supervision, approval

AI declaration

the authors use computation tool in language checking and editing.


Conflicts of interest

the authors declare no conflict of interest

REFERENCES

[1]. Souza TM, Miranda CL, Castro AB, Garcia-Bonichini PC. Risk factors associated with the use of red blood cells in elective

cardiac surgeries: a patient blood management (PBM) view. Hematol Transfus Cell Ther. 2025 Sep 17;47(4):103987. <https://doi.org/10.1016/j.htct.2025.103987>. Online ahead of print.

Hinpetch Daungsupawong ^{a,*}, Viroj Wiwanitkit ^b

^a Phonhong, Lao People's Democratic Republic

^b Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences Saveetha University, Chennai, India

*Corresponding author at: Private Academic Consultant, Phonhong, Vientiane 10000 Lao People's Democratic Republic. E-mail address: hinpetchdaung@gmail.com (H. Daungsupawong).

Received 20 September 2025

Accepted 21 October 2025

Available online xxx

<https://doi.org/10.1016/j.htct.2025.106236>

© 2025 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).